Chemical Methodologies
7.4 (Q1)
CiteScore2024
Q2
Web of Science

Molecular Docking and Pharmacokinetic Evaluation of Terpenoid Compounds from Ramie (Boehmeria nivea (L.) Gaudich.) Leaves as Potential Natural Agents for Inflammatory Bowel Disease

Document Type : Original Article

Authors

Rahadian Zainul 1, 2, 3
Iffat Syafiqoh Afif 1
Khang Wen Goh 4
Asri Peni Wulandari 5, 6
Ayu Wandira 5
Sri Benti Etika 1
Budhi Oktavia 1
Novia Nelza 7

1 Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Negeri Padang, Air Tawar Barat 25132, Padang, Indonesia

2 Center for Advanced Material Processing, Artificial Intelligence, and Biophysics Informatics (CAMPBIOTICS), Padang State University, Padang, Indonesia

3 Research Fellow, INTI International University, 71800, Nilai, Negeri Sembilan, Malaysia

4 Centre of Data Science and Sustainability Technology, Faculty Data Science and Information Technology, INTI International University, Nilai, Malaysia

5 Department of Biology, Faculty of Mathematics and Natural Science, Universitas Padjadjaran, Sumedang 45363, Indonesia

6 Center for Study of Natural Fibers and Biological Resources, Faculty of Mathematics and Natural Science, Universitas Padjadjaran, Bandung 40132, Indonesia

7 Chemical Analysis Program of Politeknik ATI Padang, Bungo Pasang Street, Tabing, Padang, Indonesia

https://doi.org/10.48309/chemm.2026.559345.2042
Abstract
Boehmeria nivea (L.) Gaudich (Ramie) is traditionally used in Indonesia as an anti-inflammatory agent, yet the molecular basis of its terpenoid activity against inflammatory bowel disease (IBD) remains poorly understood. This study aimed to characterize the pharmacokinetic properties and molecular interactions of five terpenoid compounds—Muscone, Navenone A, Jasmone, Sedanolide, and Curcumene—identified from Ramie leaves, against the IBD-related target protein CEACAM6 (PDB ID: 4Y8A) using an integrated in silico approach combining drug-likeness screening, ADMET prediction, and molecular docking. Tofacitinib, a clinically approved JAK inhibitor for IBD, was used separately as a reference (positive control) for comparison, but not classified as a terpenoid compound. All five terpenoids satisfied Lipinski’s and Veber’s criteria, showing favorable oral bioavailability, high gastrointestinal absorption, and low predicted toxicity. Docking simulations demonstrated that Muscone (-6.03 kcal/mol), Sedanolide (-5.64 kcal/mol), and Jasmone (-5.55 kcal/mol) exhibited comparable or slightly stronger binding affinities than Tofacitinib (-6.44 kcal/mol), stabilized by Zn²⁺ coordination and hydrogen bonding with catalytic residues Thr102, Glu100, and Arg39. These findings indicate that terpenoid constituents of Ramie may act as potential natural modulators of CEACAM6-mediated interactions, contributing to host-based anti-inflammatory mechanisms rather than direct enzymatic inhibition. Collectively, the results indicate that terpenoid constituents of Ramie possess multitarget anti-inflammatory potential and could serve as natural leads for IBD therapy. This research supports SDG 3 (Good Health and Well-Being) through the discovery of safer, plant-based therapeutics and SDG 12 (Responsible Consumption and Production) by promoting the sustainable utilization of local Indonesian biodiversity for biomedical innovation.

Graphical Abstract

Molecular Docking and Pharmacokinetic Evaluation of Terpenoid Compounds from Ramie (Boehmeria nivea (L.) Gaudich.) Leaves as Potential Natural Agents for Inflammatory Bowel Disease

Keywords

Boehmeria nivea
Terpenoid
CEACAM6
Molecular docking
Good health and well-being
Responsible consumption and production

Subjects

OPEN ACCESS

©2026 The author(s). This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit: http://creativecommons.org/licenses/by/4.0/

PUBLISHER NOTE

Sami Publishing Company remains neutral concerning jurisdictional claims in published maps and institutional affiliations.

CURRENT PUBLISHER

Sami Publishing Company

MAJOR DATABASES, CITATION METRICS & CAPTURES

Google Scholar | Scopus - SJR | Web of Science | PlumX Metrics |

[1]     Yeshi, K., Ruscher, R., Hunter, L., Daly, N.L., Loukas, A., Wangchuk, P. Revisiting inflammatory bowel disease: Pathology, treatments, challenges and emerging therapeutics including drug leads from natural products. Journal of Clinical Medicine, 2020, 9(5), 1273.
[2]     Wei, S.C., Sollano, J., Hui, Y.T., Yu, W., Santos Estrella, P.V., Llamado, L.J.Q., Koram, N. Epidemiology, burden of disease, and unmet needs in the treatment of ulcerative colitis in Asia. Expert Review of Gastroenterology & Hepatology, 2021, 15(3), 275-289.
[3]     Caruso, R., Lo, B.C., Núñez, G. Host–microbiota interactions in inflammatory bowel disease. Nature Reviews Immunology, 2020, 20(7), 411-426.
[4]     Palmela, C., Chevarin, C., Xu, Z., Torres, J., Sevrin, G., Hirten, R., Colombel, J.F. Adherent-invasive Escherichia coli in inflammatory bowel disease. Gut, 2018, 67(3), 574-587.
[5]     Perna, A., Hay, E., Contieri, M., De Luca, A., Guerra, G., Lucariello, A. Adherent-invasive Escherichia coli (AIEC): Cause or consequence of inflammation, dysbiosis, and rupture of cellular joints in patients with IBD? Journal of Cellular Physiology, 2020, 235(6), 5041-5049.
[6]     Saiz-Gonzalo, G., Hanrahan, N., Rossini, V., Singh, R., Ahern, M., Kelleher, M., Walsh, P.T. Regulation of CEACAM family members by IBD-associated triggers in intestinal epithelial cells, their correlation to inflammation and relevance to IBD pathogenesis. Frontiers in Immunology, 2021, 12, 655960.
[7]     Kelleher, M., Singh, R., O’Driscoll, C.M., Melgar, S. Carcinoembryonic antigen (CEACAM) family members and inflammatory bowel disease. Cytokine & Growth Factor Reviews, 2019, 47, 21-31.
[8]     Glas, J., Seiderer, J., Fries, C., Tillack, C., Pfennig, S., Weidinger, M., Göke, B. CEACAM6 gene variants in inflammatory bowel disease. PloS One, 2011, 6(4), e19319.
[9]     Barnich, N., Carvalho, F.A., Glasser, A.L., Darcha, C., Jantscheff, P., Allez, M., Colombel, J.F. CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. The Journal of Clinical Investigation, 2007, 117(6), 1566-1574.
[10] Stein, R.B., Hanauer, S.B. Comparative tolerability of treatments for inflammatory bowel disease. Drug Safety, 2000, 23(5), 429-448.
[11] Kumari, R., Negi, M., Thakur, P., Mahajan, H., Raina, K., Sharma, R., Singh, R., Anand, V., Ming, L.C., Goh, K.W., Calina, D., Saussurea costus (Falc.) Lipsch.: A comprehensive review of its pharmacology, phytochemicals, ethnobotanical uses, and therapeutic potential. Naunyn-Schmiedeberg's Archives of Pharmacology, 2024, 397(3), 1505-1524.
[12] Viola, A., Caltagirone, A.M., Campisi, G., Guarneri, G., Cappello, M. Stevens-Johnson syndrome on treatment with sulfasalazine for Crohn’s disease: Need for a multidisciplinary approach. The Turkish Journal of Gastroenterology, 2018, 30(2), 211.
[13] Ansori, A.N.M., Widyananda, M.H., Antonius, Y., Murtadlo, A.A.A., Kharisma, V.D., Wiradana, P.A., Sahadewa, S., Durry, F.D., Maksimiuk, N., Rebezov, M. and Zainul, R., A review of cancer-related hypercalcemia: Pathophysiology, current treatments, and future directions. Journal of Medicinal and Pharmaceutical Chemistry Research, 2024, 6(7), 944-952.
[14] Sarkar, A., Bhattacharjee, S. Terpenoids in treatment of immunological disease. In: Terpenoids Against Human Diseases. CRC Press; 2019, 119–175.
[15] Sarwar, R., Maisam, M., Khan, M.W., Xue, Y., Hassan, S.  Bioactive compounds in herbal remedies. In: Herbal Pharmacopeia. CRC Press; 2025, 89–121.
[16] Ku, C.M., Lin, J.Y. Anti-inflammatory effects of 27 selected terpenoid compounds tested through modulating Th1/Th2 cytokine secretion profiles using murine primary splenocytes. Food Chemistry, 2013, 141(2), 1104-1113.
[17] Leite, PM., Amorim, JM., Castilho RO. Immunomodulatory role of terpenoids and phytosteroids. In: Plants and Phytomolecules for Immunomodulation, 2022, 321–360.
[18] Prakash, V. Terpenoids as source of anti-inflammatory compounds. Asian Journal of Pharmaceutical and Clinical Research, 2017, 10(3), 68-76.
[19] Wang, C.Y., Chen, Y.W., Hou, C.Y. Antioxidant and antibacterial activity of seven predominant terpenoids. International Journal of Food Properties, 2019, 22(1), 230-238.
[20] Graßmann, J. Terpenoids as plant antioxidants. Vitamins & Hormones, 2005, 72, 505-535.
[21] El Hachlafi, N., Fikri-Benbrahim, K., Al-Mijalli, S.H., Elbouzidi, A., Jeddi, M., Abdallah, E.M., Assaggaf, H., Bouyahya, A., Alnasser, S.M., Attar, A., Goh, K.W. Tetraclinis articulata (Vahl) Mast. essential oil as a promising source of bioactive compounds with antimicrobial, antioxidant, anti-inflammatory and dermatoprotective properties: In vitro and in silico evidence. Heliyon, 2024, 10(1).
[22] Kim, T., Song, B., Cho, K.S., Lee, I.S. Therapeutic potential of volatile terpenes and terpenoids from forests for inflammatory diseases. International Journal of Molecular Sciences, 2020, 21(6), 2187.
[23] Devi, M., Bamrah, P.K., Goyal, R., Choudhary, M., Chopra, H. Insights on the emerging therapeutic potential of terpenoids as anti-inflammatory agents: A scoping review. Journal of Bio-X Research, 2024, 7, 0006.
[24] Yu, L., Qiu, G., Yu, X., Zhao, J., Liu, J., Wang, H., Dong, L. Terpinen-4-ol Improves the Intestinal Barrier Function of the Colon in Immune-Stressed Weaning Piglets. Animals, 2024, 15(1), 9.
[25]           Velayutham, N.K., Thamaraikani, T., Wahab, S., Khalid, M., Ramachawolran, G., Abullais, S.S., Wong, L.S., Sekar, M., Gan, S.H., Ebenezer, A.J., Ravikumar, M. Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy. Frontiers in Pharmacology, 2023, 14, 1150270.
[26] Mawaddani, N., Sutiyanti, E., Hermawan Widyananda, M. In silico study of entry inhibitor from Moringa oleifera bioactive compounds against SARS-CoV-2 infection. Pharmacognosy Journal, 2022, 14(5).
[27] Arsul, M.I., Insanu, M., Fidrianny, I. Phytochemistry and pharmacological activities of Boehmeria genus: An update review. Pharmacognosy Journal, 2021, 13(6).
[28]           Kiruthika, M., Raveena, R., Yogeswaran, R., Elangovan, N., Arumugam, N., Padmanaban, R., Djearamane, S., Wong, L.S., Kayarohanam, S. Spectroscopic characterization, DFT, antimicrobial activity and molecular docking studies on 4, 5-bis [(E)-2-phenylethenyl]-1H, 1′ H-2, 2′-biimidazole. Heliyon, 2024, 10(9).
[29] Rahman, A.T., Jethro, A., Santoso, P., Kharisma, V.D., Murtadlo, A.A.A., Purnamasari, D., Soekamto, N.H., Ansori, A.N.M., Mandeli, R.S., Aledresi, K.A.M.S., Yusof, N.F.M. In silico study of the potential of endemic sumatra wild turmeric rhizomes (Curcuma Sumatrana: Zingiberaceae) as anti-cancer. Pharmacognosy Journal, 2022, 14(6).
[30] Wandira, A., Janitra, R., Satria, Zainul, R., Wulandari, A. Ramie (Boehmeria Nivea) as a Source of Natural Anti-Inflammatory Compounds: In Silico Evaluation of Potential for Inflammatory Bowel Disease Therapy. Asian Journal of Green Chemistry, 2025, 9(6), 751-774.
[31] Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 1997, 23(1-3), 3-25.
[32] Iacopetta, D., Ceramella, J., Catalano, A., Scali, E., Scumaci, D., Pellegrino, M., Sinicropi, M.S. Impact of cytochrome P450 enzymes on the phase I metabolism of drugs. Applied Sciences, 2023, 13(10), 6045.
[33] Stéen, E.J.L., Vugts, D.J., Windhorst, A.D. The application of in silico methods for prediction of blood-brain barrier permeability of small molecule PET tracers. Frontiers in Nuclear Medicine, 2022, 2, 853475.
[34] Filimonov, D.A., Rudik, A.V., Dmitriev, A.V., Poroikov, V.V. Computer-aided estimation of biological activity profiles of drug-like compounds taking into account their metabolism in human body. International Journal of Molecular Sciences, 2020, 21(20), 7492.
[35] Wang, J., Xing, H., Qin, X., Ren, Q., Yang, J., Li, L. Pharmacological effects and mechanisms of muscone. Journal of Ethnopharmacology, 2020, 262, 113120.
[36] Wang, X., Zhao, X., Li, X., Li, F., Jie, H., Li, X. A comprehensive update on synthesis, pharmacokinetics, bioactivities, therapeutic potential, and future prospects of muscone. Natural Product Research, 2025, 1-14.
[37] Jain, H., Dhingra, N., Narsinghani, T., Sharma, R. Insights into the mechanism of natural terpenoids as NF-κB inhibitors: An overview on their anticancer potential. Experimental Oncology, 2016,
[38] Urošević, M., Nikolić, L., Gajić, I., Nikolić, V., Dinić, A., Miljković, V. Curcumin: Biological activities and modern pharmaceutical forms. Antibiotics, 2022, 11(2), 135.
[39] Jarocka-Karpowicz, I., Markowska, A. Therapeutic potential of jasmonic acid and its derivatives. International Journal of Molecular Sciences, 2021, 22(16), 8437.
[40] Husain, D.R., Wardhani, R. Antibacterial activity of endosymbiotic bacterial compound from Pheretima sp. earthworms inhibit the growth of Salmonella Typhi and Staphylococcus aureus: in vitro and in silico approach. Iranian Journal of Microbiology, 2021, 13(4), 537.
[41] Fatima, K., Asif, M., Farooq, U., Gilani, S.J., Bin Jumah, M.N., Ahmed, M.M. Antioxidant and anti-inflammatory applications of Aerva persica aqueous-root extract-mediated synthesis of ZnO nanoparticles. ACS Omega, 2024, 9(14), 15882-15892.
[42] Susetyarini, E., Wahyono, P., Wahyuni, S., Nurrohman, E., Zainul, R. Impact of Stigmasterol from Beluntas Leaves (Pluchea indica) on SGOT and SGPT Levels in Male Rats (Rattus norvegicus). Pharmacognosy Journal, 2024, 16(6).
[43] Bhupatiraju, L., Bethala, K., Goh, K.W., Dhaliwal, J.S., Siang, T.C., Menon, S., Ming, L.C. Influence of Murraya koenigii extract on diabetes induced rat brain aging. Journal of Medicine and Life, 2023, 16(2), 307.
[44] Fadlan, A., Warsito, T., Sarmoko, S. Evaluasi parameter fisikokimia, farmakokinetika, dan farmakodinamika senyawa fisetin dalam desain obat. Akta Kimia Indonesia, 2022, 7(1), 1-13.
[45] Smart, O.S., Horský, V., Gore, S., Svobodová Vařeková, R., Bendová, V., Kleywegt, G.J., Velankar, S. Validation of ligands in macromolecular structures determined by X-ray crystallography. Biological Crystallography, 2018, 74(3), 228-236.
[46] Bonsor, D.A., Günther, S., Beadenkopf, R., Beckett, D., Sundberg, E.J. Diverse oligomeric states of CEACAM IgV domains. Proceedings of the National Academy of Sciences, 2015, 112(44), 13561-13566.
 
Chemical Methodologies
Volume 10, Issue 5
May 2026
Pages 489-503

XML
PDF 1.19 M
Podcasts

  • Receive Date 12 November 2025
  • Revise Date 26 December 2025
  • Accept Date 08 January 2026

Home

A-Z Journals

SPC Publisher's policies

Submit Manuscript

Guide for Authors

Indexing and Abstracting

Editorial Board

Using and Citation

Contact Us